France · Delayed Price · Currency is EUR Innate Pharma Statistics
Total Valuation
Innate Pharma has a market cap or net worth of EUR 118.63 million. The enterprise value is 127.94 million.
| Market Cap | 118.63M |
| Enterprise Value | 127.94M |
Important Dates
The last earnings date was Thursday, September 17, 2026.
| Earnings Date | Sep 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Innate Pharma has 93.70 million shares outstanding. The number of shares has increased by 10.65% in one year.
| Current Share Class | 93.70M |
| Shares Outstanding | 93.70M |
| Shares Change (YoY) | +10.65% |
| Shares Change (QoQ) | +1.71% |
| Owned by Insiders (%) | 0.74% |
| Owned by Institutions (%) | 1.49% |
| Float | 70.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 1.00 |
| PS Ratio | 12.52 |
| PB Ratio | -3.03 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.60
| Current Ratio | 0.60 |
| Quick Ratio | 0.47 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.47 |
| Interest Coverage | -124.92 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -46.60% |
| Return on Invested Capital (ROIC) | -2,545.08% |
| Return on Capital Employed (ROCE) | -2,545.08% |
| Weighted Average Cost of Capital (WACC) | 9.47% |
| Revenue Per Employee | 81,733 |
| Profits Per Employee | -395,467 |
| Employee Count | 120 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -26.82% in the last 52 weeks. The beta is 1.19, so Innate Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.19 |
| 52-Week Price Change | -26.82% |
| 50-Day Moving Average | 1.64 |
| 200-Day Moving Average | 1.50 |
| Relative Strength Index (RSI) | 23.07 |
| Average Volume (20 Days) | 299,755 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Innate Pharma had revenue of EUR 9.81 million and -47.46 million in losses. Loss per share was -0.51.
| Revenue | 9.81M |
| Gross Profit | -30.17M |
| Operating Income | -47.59M |
| Pretax Income | -47.46M |
| Net Income | -47.46M |
| EBITDA | -46.96M |
| EBIT | -47.59M |
| Loss Per Share | -0.51 |
Balance Sheet
The company has 10.90 million in cash and 20.21 million in debt, with a net cash position of -9.31 million or -0.10 per share.
| Cash & Cash Equivalents | 10.90M |
| Total Debt | 20.21M |
| Net Cash | -9.31M |
| Net Cash Per Share | -0.10 |
| Equity (Book Value) | -40.51M |
| Book Value Per Share | -0.43 |
| Working Capital | -13.26M |
Cash Flow
In the last 12 months, operating cash flow was -42.64 million and capital expenditures -172,000, giving a free cash flow of -42.81 million.
| Operating Cash Flow | -42.64M |
| Capital Expenditures | -172,000 |
| Depreciation & Amortization | 631,000 |
| Net Borrowing | -6.82M |
| Free Cash Flow | -42.81M |
| FCF Per Share | -0.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | -485.25% |
| Pretax Margin | -483.85% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Innate Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.65% |
| Shareholder Yield | -10.65% |
| Earnings Yield | -38.66% |
| FCF Yield | -34.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Innate Pharma is 5.90, which is 366.04% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 5.90 |
| Price Target Difference | 366.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 124.72% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Innate Pharma has an Altman Z-Score of -21.88 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.88 |
| Piotroski F-Score | 3 |